Andrew Abba Stolz, MD

TitleAssociate Professor of Medicine
InstitutionUniversity of Southern California
AddressHMR 101
Health Sciences Campus
Los Angeles CA 90089-9091
Phone+1 323 442 2699
vCardDownload vCard
    Other Positions
    TitleAssociate Chair For Faculty Affairs For The Department of Medicine

    Collapse Biography 
    Collapse Awards and Honors
    American Liver Foundation1983  - 1985Postdoctoral Fellowship
    17th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology2006Fabre Laboratories Best Poster

    Collapse Overview 
    Collapse Overview
    Dr. Stolz's major areas of research interest are mechanisms of protein mediated intracellular transport of bile acids in the liver, molecular characterization of Aldo-Keto Reductase supergene family members in rat, mouse and human, dysregulation of hormone catabolism in human breast and prostate cancers, and drug-induced liver injury, among others.

    Dr. Stolz earned his medical degree at Albert Einstein College of Medicine. He then performed his residency at Mt. Sinai Hospital, immediately followed by a Gastroenterology Fellowship at UCLA. Dr. Stolz has been a part of the Division of Gastrointestinal and Liver Diseases since 1990, earning tenure shortly after.

    Collapse Research 
    Collapse Research Activities and Funding
    USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center.
    NIH/NIDDK U01DK083020Sep 30, 2008 - Jun 30, 2018
    Role: Principal Investigator
    Targeting DHT Catabolism by AKR1Cs for Prostrate Cancer Prevention and Treatment.
    NIH/NCI R01CA122247Dec 3, 2007 - Mar 31, 2013
    Role: Principal Investigator
    NIH/NIDDK R01DK041014Jan 1, 1989 - Apr 30, 1999
    Role: Principal Investigator
    NIH/NIDDK R29DK041014Jan 1, 1989 - Apr 30, 1994
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Bonkovsky HL, Barnhart HX, Foureau DM, Steuerwald N, Lee WM, Gu J, Fontana RJ, Hayashi PJ, Chalasani N, Navarro VM, Odin J, Stolz A, Watkins PB, Serrano J. Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group. PLoS One. 2018; 13(10):e0206389. PMID: 30359443.
      View in: PubMed
    2. Ahmad J, Rossi S, Rodgers SK, Ghabril M, Fontana RJ, Stolz A, Hayashi PH, Barnhart H, Kleiner DE, Bjornsson ES. Sclerosing Cholangitis Like Changes on Magnetic Resonance Cholangiography in Patients with Drug Induced Liver Injury. Clin Gastroenterol Hepatol. 2018 Jun 29. PMID: 29966706.
      View in: PubMed
    3. Roth NC, Saberi B, Macklin J, Kanel G, French SW, Govindarajan S, Buzzanco AS, Stolz AA, Donovan JA, Kaplowitz N. Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy. Hepatol Commun. 2017 Dec; 1(10):1070-1084. PMID: 29404443.
      View in: PubMed
    4. Chalasani N, Reddy KRK, Fontana RJ, Barnhart H, Gu J, Hayashi PH, Ahmad J, Stolz A, Navarro V, Hoofnagle JH. Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. Am J Gastroenterol. 2017 Sep; 112(9):1382-1388. PMID: 28762375.
      View in: PubMed
    5. Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, Aithal GP, Dillon J, Navarro V, Odin J, Barnhart H, Ostrov D, Long N, Cirulli ET, Watkins PB, Fontana RJ. Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. J Hepatol. 2017 Jul; 67(1):137-144. PMID: 28323125.
      View in: PubMed
    6. Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology. 2017 04; 152(5):1078-1089. PMID: 28043905.
      View in: PubMed
    7. Heidemann LA, Navarro VJ, Ahmad J, Hayashi PH, Stolz A, Kleiner DE, Fontana RJ. Erratum to: Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci. 2016 Dec; 61(12):3638. PMID: 27714508.
      View in: PubMed
    8. Heidemann LA, Navarro VJ, Ahmad J, Hayashi PH, Stolz A, Kleiner DE, Fontana RJ. Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci. 2016 09; 61(9):2741-8. PMID: 27142670; PMCID: PMC4982804 [Available on 09/01/17].
    9. Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana RJ, Russo MW. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 2016 Apr; 36(4):603-9. PMID: 26601797; PMCID: PMC5035108.
    10. Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015 Oct; 110(10):1450-9. PMID: 26346867; PMCID: PMC4784423 [Available on 10/01/16].
    11. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015 Jun; 148(7):1340-52.e7. PMID: 25754159.
      View in: PubMed
    12. Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol. 2015 Sep; 13(9):1676-82.e1. PMID: 25724701.
      View in: PubMed
    13. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J, Sherker AH, Stolz A, Talwalkar J, Vega M, Vuppalanchi R. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014 Oct; 60(4):1399-408. PMID: 25043597; PMCID: PMC4293199.
    14. Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, Gu J, Hoofnagle JH, Chalasani N. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):369-376.e3. PMID: 25111234.
      View in: PubMed
    15. Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, Reddy KR, Stolz AA, Hoofnagle JH, Rockey DC. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int. 2015 May; 35(5):1623-32. PMID: 24661785; PMCID: PMC4305346.
    16. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014 Jul; 147(1):96-108.e4. PMID: 24681128.
      View in: PubMed
    17. Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N, Fontana RJ, Watkins PB, Lee WM, Reddy KR, Stolz A, Talwalkar J, Davern T, Saha D, Bell LN, Barnhart H, Gu J, Serrano J, Bonkovsky HL. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One. 2013; 8(12):e81974. PMID: 24386086; PMCID: PMC3873930.
    18. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014 Feb; 59(2):661-70. PMID: 24037963; PMCID: PMC3946736.
    19. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012 Nov; 22(11):784-95. PMID: 22968431; PMCID: PMC3636716.
    20. Lee RH, Stanczyk FZ, Stolz A, Ji Q, Yang G, Goodwin TM. AKR1C1 and SRD5A1 messenger RNA expression at term in the human myometrium and chorioamniotic membranes. Am J Perinatol. 2008 Oct; 25(9):577-82. PMID: 18770491.
      View in: PubMed
    21. Steiner AZ, Chang L, Ji Q, Ookhtens M, Stolz A, Paulson RJ, Stanczyk FZ. 3alpha-Hydroxysteroid dehydrogenase type III deficiency: a novel mechanism for hirsutism. J Clin Endocrinol Metab. 2008 Apr; 93(4):1298-303. PMID: 18252781; PMCID: PMC2291485.
    22. Ji Q, Chang L, Stanczyk FZ, Ookhtens M, Sherrod A, Stolz A. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res. 2007 Feb 01; 67(3):1361-9. PMID: 17283174.
      View in: PubMed
    23. Lou H, Du S, Ji Q, Stolz A. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by NRF2. Mol Pharmacol. 2006 May; 69(5):1662-72. PMID: 16478829.
      View in: PubMed
    24. Ji Q, Aoyama C, Chen PK, Stolz A, Liu P. Localization and altered expression of AKR1C family members in human ovarian tissues. Mol Cell Probes. 2005 Aug; 19(4):261-6. PMID: 15979276.
      View in: PubMed
    25. Ji Q, Liu PI, Elshimali Y, Stolz A. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol Cell Endocrinol. 2005 Jan 14; 229(1-2):103-10. PMID: 15607534.
      View in: PubMed
    26. Ji Q, Aoyama C, Nien YD, Liu PI, Chen PK, Chang L, Stanczyk FZ, Stolz A. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 2004 Oct 15; 64(20):7610-7. PMID: 15492289.
      View in: PubMed
    27. Lou H, Ookhtens M, Stolz A, Kaplowitz N. Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells. Am J Physiol Gastrointest Liver Physiol. 2003 Dec; 285(6):G1335-44. PMID: 12893631.
      View in: PubMed
    28. Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, Stolz A. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate. 2003 Mar 01; 54(4):275-89. PMID: 12539226.
      View in: PubMed
    29. Vergnes L, Phan J, Stolz A, Reue K. A cluster of eight hydroxysteroid dehydrogenase genes belonging to the aldo-keto reductase supergene family on mouse chromosome 13. J Lipid Res. 2003 Mar; 44(3):503-11. PMID: 12562828.
      View in: PubMed